HAG
NRXP icon

HighPoint Advisor Group’s NRX Pharmaceuticals NRXP Stock Holding History

HighPoint Advisor Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,350
Closed -$23K – 660
2023
Q4 		$23K Buy
+4,350
New +$14.4K ﹤0.01% 634
2022
Q2 		$24K Buy
+4,350
New +$57.1K ﹤0.01% 521
2021
Q3 		$403K Hold
4,350
– – 0.04% 347
2021
Q2 		$505K Buy
+4,350
New +$1.15M 0.05% 296

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

HighPoint Advisor Group's NRXP Position: Q1 2024 in Review

HighPoint Advisor Group sold out of NRX Pharmaceuticals (NRXP) in Q1 2024, closing a stake of 4,350 shares — an estimated $23K sold.

HighPoint Advisor Group first reported a position in NRXP in Q2 2021 and held it in 4 quarters. The position peaked at $505K in Q2 2021. 31 funds tracked by Wall St. Rank hold NRXP as of Q1 2024.

  • HighPoint Advisor Group reported no remaining NRX Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • HighPoint Advisor Group sold 4,350 NRX Pharmaceuticals shares in Q1 2024, an estimated $23K.
  • HighPoint Advisor Group first reported a position in NRX Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • HighPoint Advisor Group's NRX Pharmaceuticals position peaked at $505K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2024.

Based on HighPoint Advisor Group's 13F filing for Q1 2024, filed 14 May 2024.